Timothy Kieffer
Direttore Tecnico/Scientifico/R&S presso FRACTYL HEALTH, INC.
Patrimonio netto: - $ in data 30/04/2024
Profilo
Timothy Kieffer is currently the Chief Scientific Officer at Fractyl Health, Inc. He previously held the position of Chief Scientific Officer at ViaCyte, Inc. from 2021 to 2022.
Prior to his industry roles, he worked as a Professor at the University of British Columbia.
Dr. Kieffer obtained a doctorate degree from the University of British Columbia.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
FRACTYL HEALTH, INC.
-.--% | 15/03/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Posizioni attive di Timothy Kieffer
| Società | Posizione | Inizio |
|---|---|---|
| FRACTYL HEALTH, INC. | Direttore Tecnico/Scientifico/R&S | 01/09/2023 |
Precedenti posizioni note di Timothy Kieffer
| Società | Posizione | Fine |
|---|---|---|
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Direttore Tecnico/Scientifico/R&S | 01/10/2022 |
| University of British Columbia | Corporate Officer/Principal | - |
Formazione di Timothy Kieffer
| University of British Columbia | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| FRACTYL HEALTH, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
- Borsa valori
- Insiders
- Timothy Kieffer
